Latest news on bedaquiline in 2024

The main advantage of Bedaquiline (Bedaquiline) is that it also has good antibacterial activity against Mycobacterium tuberculosis that is resistant to other anti-tuberculosis drugs. This means that bedaquiline remains an important treatment option for patients who have developed resistance to traditional anti-tuberculosis drugs. In clinical trials, bedaquiline has been proven to be used in combination with other anti-tuberculosis drugs to significantly shorten the treatment time of patients, increase the rate of sputum negative conversion, and reduce the incidence of drug-resistant cases. Compared with conventional therapy, patients using bedaquiline combined with conventional therapy had significantly higher sputum negative conversion rates after 8 and 24 weeks of treatment. Although some adverse effects and side effects have been reported, most are mild to moderate and can be controlled and managed.